NCHR Author

NCHR Comments at the Risk Communication Advisory Committee on Pregnancy and Lactation Labeling Rule

March 5, 2018. Pregnancy/postpartum represent critical periods for counseling, health promotion, and health maintenance. Providers and patients must engage in informed discussions of benefits, risks, and alternatives in order to achieve shared-decision making. However, uncertainty of drug harms present a unique challenge in the overall picture of risks and benefits.

Exercise Helps Older People Stay Sharp and Remember More

Exercise has so many health benefits, but did you know that it is also a fountain of youth for our brains? Some research suggests that, just by being active, seniors can improve their ability to think, focus, plan, and recall words, as well as perform many other brain activities.

Ten Easy Tips to Get Your Family Eating Healthy

Does switching to healthier foods seem like an impossible chore? It doesn’t have to be! Change your habits gradually with these 10 simple tips.

NCHR Comments on Changes to Medical Software Policies Due to 21st Century Cures Act

February 15, 2018. The draft guidance Changes to Existing Medical Software Policies Resulting from Section 3060 of the 21st Century Cures Act removes FDA evaluation of EHRs and leaves only certification by the Office of the National Coordinator for Health Information Technology (ONC) to ensure that software is both functional for providers and safe for patients. However, ONC certification is not sufficient to protect patients from problems with EHR software. For that reason, the draft guidance as written puts patients’ lives at risk.

NCHR Testimony at FDA About New Opioid Combination, Hydexor

February 14, 2018. Consider how this drug fits into the context of the drug market and how it is likely to be used or misused. Do the benefits outweigh the risks of putting another conventional opioid on the market, one that is designed to treat its own side effects, and are the attempts to reduce excess pills sufficient? Opioids provide both a benefit and a harm in our society. As Advisory Board members, please advise the FDA to carefully and cautiously consider the potential for abuse of this opioid.